story of the week
Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial
Lancet 2019 Jun 07;[EPub Ahead of Print], HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, J Probstfield, JS Riesmeyer, MC Riddle, L Rydén, D Xavier, CM Atisso, L Dyal, S Hall, P Rao-Melacini, G Wong, A Avezum, J Basile, N Chung, I Conget, WC Cushman, E Franek, N Hancu, M Hanefeld, S Holt, P Jansky, M Keltai, F Lanas, LA Leiter, P Lopez-Jaramillo, EG Cardona Munoz, V Pirags, N Pogosova, PJ Raubenheimer, JE Shaw, WH Sheu, T Temelkova-KurktschievFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.